ResMed Inc.
NYSE:RMDMedical - Devices
+$1.58 today
- Market cap
- $34.12B
- Beta
- 0.78
- P/E (TTM)
- 18.1
- EPS (TTM)
- $10.37
- Dividend yield
- 1.28%
Volume 1.22M
Average 1.32M
RMD Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
ResMed Inc.NYSE: RMD
Cost of Revenue · Q4 FY2026 · quarter ended Jun 2026
Cost of revenue growth accelerates
Q4 FY2026 cost of revenue of $602.43M rose 14.1% year over year, ahead of the +5.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +5.6% a year.
Context
- Cost of revenue amounted to 38.9% of revenue in FY2026, down 1.7 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +14.1% holds above the trailing-twelve-month pace of +5.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2026
- 2.2B USD
- Year-over-year change
- +5.3%
- 4-year CAGR
- +9.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 2.2B | +5.3% |
| FY2025 | 2025-06-30 | 2.09B | +3.0% |
| FY2024 | 2024-06-30 | 2.03B | +8.7% |
| FY2023 | 2023-06-30 | 1.87B | +20.2% |
| FY2022 | 2022-06-30 | 1.55B | — |
Cost of Revenue vs competitors
How RMD compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.0% is the 3rd highest of 9, against a peer median of -2.9%.
- Cost of revenue amounts to 38.8% of revenue for RMD, versus a peer median of 33.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $12.51B USD | +0.0% | +5.9% | 33.3% | |
| LTM Jun 2026 | $11.56B USD | -1.0% | +3.5% | 57.1% | |
| LTM Jun 2026 | €9.55B EUR | -4.7% | -2.8% | 54.1% | |
| LTM Jun 2026 | $6.06B USD | -11.0% | +7.8% | 28.8% | |
| LTM Sep 2026 | $3.8B USD | +17.5% | +19.1% | 32.8% | |
| LTM Jun 2026 | $2.2B USD | +5.0% | +5.6% | 38.8% | |
| LTM Jun 2026 | $1.2B USD | -11.0% | -11.5% | 46.2% | |
| LTM Jun 2026 | $124.64M USD | -6.8% | +26.3% | 13.9% | |
| LTM Mar 2026 | $15.47M USD | +12.2% | +11.1% | 21.6% | |
| Peer median (excluding RMD) | — | -2.9% | +6.8% | 33.1% | |
Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 3.58B | 4.22B | 4.69B | 5.15B | 5.65B |
| Cost of Revenue | 1.55B | 1.87B | 2.03B | 2.09B | 2.2B |
| Gross Profit | 2.02B | 2.36B | 2.66B | 3.05B | 3.45B |
| Gross Margin | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| Research & Development | 253.58M | 287.64M | 307.53M | 331.28M | 378.29M |
| Selling, General & Admin | 739.37M | 874M | 917.14M | 991.02M | 1.12B |
| Operating Expenses | 1.02B | 1.22B | 1.34B | 1.37B | 1.54B |
| Depreciation & Amortization | 193.84M | 197.56M | 216.21M | 235.81M | 244.15M |
| EBITDA | 1.18B | 1.36B | 1.53B | 1.91B | 2.15B |
| EBITDA Margin | 32.9% | 32.2% | 32.7% | 37.2% | 38.1% |
| Operating Income | 1B | 1.13B | 1.32B | 1.69B | 1.91B |
| Operating Margin | 28.0% | 26.8% | 28.2% | 32.7% | 33.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.31M | 47.38M | 45.71M | 12.61M | 0 |
| Other Income / Expenses | (39.8M) | (30.21M) | (55.1M) | (7.8M) | 10.96M |
| Income Before Tax | 960.48M | 1.1B | 1.26B | 1.68B | 1.92B |
| Pre-Tax Margin | 26.8% | 26.1% | 27.0% | 32.6% | 34.0% |
| Income Tax Expense | 181.05M | 204.11M | 243.85M | 276.84M | 396.12M |
| Net Income | 779.44M | 897.56M | 1.02B | 1.4B | 1.52B |
| Net Margin | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| EPS (Basic) | 5.34 | 6.12 | 6.94 | 9.55 | 10.44 |
| EPS (Diluted) | 5.30 | 6.09 | 6.92 | 9.51 | 10.40 |
| Weighted Avg Shares | 146.07M | 146.77M | 147.02M | 146.72M | 144.71M |
| Weighted Avg Shares (Diluted) | 147.04M | 147.46M | 147.55M | 147.34M | 144.98M |
ResMed Inc.
NYSE:RMD
Intrinsic Alpha fair value
Locked
Current Price
$242.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.